Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site

Ji Yuan, David A. Stein, Travis Lim, Dexin Qiu, Shaun Coughlin, Zhen Liu, Yinjing Wang, Robert Blouch, Hong M. Moulton, Patrick L. Iversen, Decheng Yang

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Coxsackievirus B3 (CVB3) is a primary cause of viral myocarditis, yet no effective therapeutic against CVB3 is available. Nucleic acid-based interventional strategies against various viruses, including CVB3, have shown promise experimentally, but limited stability and inefficient delivery in vivo remain as obstacles to their potential as therapeutics. We employed phosphorodiamidate morpholino oligomers (PMO) conjugated to a cell-penetrating arginine-rich peptide, P007 (to form PPMO), to address these issues. Eight CVB3-specifflc PPMO were evaluated with HeLa cells and HL-1 cardiomyocytes in culture and in a murine infection model. One of the PPMO (PPMO-6), designed to target a sequence in the 3′ portion of the CVB3 internal ribosomal entry site, was found to be especially potent against CVB3. Treatment of cells with PPMO-6 prior to CVB3 infection produced an approximately 3-log10 decrease in viral titer and largely protected cells from a virus-induced cytopathic effect. A similar antiviral effect was observed when PPMO-6 treatment began shortly after the virus infection period. A/J mice receiving intravenous administration of PPMO-6 once prior to and once after CVB3 infection showed an ∼2-log10-decreased viral titer in the myocardium at 7 days postinfection and a significantly decreased level of cardiac tissue damage, compared to the controls. Thus, PPMO-6 provided potent inhibition of CVB3 amplification both in cell cultures and in vivo and appears worthy of further evaluation as a candidate for clinical development.

Original languageEnglish (US)
Pages (from-to)11510-11519
Number of pages10
JournalJournal of virology
Volume80
Issue number23
DOIs
StatePublished - Dec 1 2006

Fingerprint

Morpholinos
Enterovirus
ribosomes
cell culture
Cell Culture Techniques
peptides
Peptides
mice
Coxsackievirus Infections
viral load
infection
viruses
Viruses
Myocarditis
cells
Virus Diseases
Therapeutics
Internal Ribosome Entry Sites
HeLa Cells
Cardiac Myocytes

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. / Yuan, Ji; Stein, David A.; Lim, Travis; Qiu, Dexin; Coughlin, Shaun; Liu, Zhen; Wang, Yinjing; Blouch, Robert; Moulton, Hong M.; Iversen, Patrick L.; Yang, Decheng.

In: Journal of virology, Vol. 80, No. 23, 01.12.2006, p. 11510-11519.

Research output: Contribution to journalArticle

Yuan, J, Stein, DA, Lim, T, Qiu, D, Coughlin, S, Liu, Z, Wang, Y, Blouch, R, Moulton, HM, Iversen, PL & Yang, D 2006, 'Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site', Journal of virology, vol. 80, no. 23, pp. 11510-11519. https://doi.org/10.1128/JVI.00900-06
Yuan, Ji ; Stein, David A. ; Lim, Travis ; Qiu, Dexin ; Coughlin, Shaun ; Liu, Zhen ; Wang, Yinjing ; Blouch, Robert ; Moulton, Hong M. ; Iversen, Patrick L. ; Yang, Decheng. / Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. In: Journal of virology. 2006 ; Vol. 80, No. 23. pp. 11510-11519.
@article{d1c04e159c9c4a399f90c71487b0e25e,
title = "Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site",
abstract = "Coxsackievirus B3 (CVB3) is a primary cause of viral myocarditis, yet no effective therapeutic against CVB3 is available. Nucleic acid-based interventional strategies against various viruses, including CVB3, have shown promise experimentally, but limited stability and inefficient delivery in vivo remain as obstacles to their potential as therapeutics. We employed phosphorodiamidate morpholino oligomers (PMO) conjugated to a cell-penetrating arginine-rich peptide, P007 (to form PPMO), to address these issues. Eight CVB3-specifflc PPMO were evaluated with HeLa cells and HL-1 cardiomyocytes in culture and in a murine infection model. One of the PPMO (PPMO-6), designed to target a sequence in the 3′ portion of the CVB3 internal ribosomal entry site, was found to be especially potent against CVB3. Treatment of cells with PPMO-6 prior to CVB3 infection produced an approximately 3-log10 decrease in viral titer and largely protected cells from a virus-induced cytopathic effect. A similar antiviral effect was observed when PPMO-6 treatment began shortly after the virus infection period. A/J mice receiving intravenous administration of PPMO-6 once prior to and once after CVB3 infection showed an ∼2-log10-decreased viral titer in the myocardium at 7 days postinfection and a significantly decreased level of cardiac tissue damage, compared to the controls. Thus, PPMO-6 provided potent inhibition of CVB3 amplification both in cell cultures and in vivo and appears worthy of further evaluation as a candidate for clinical development.",
author = "Ji Yuan and Stein, {David A.} and Travis Lim and Dexin Qiu and Shaun Coughlin and Zhen Liu and Yinjing Wang and Robert Blouch and Moulton, {Hong M.} and Iversen, {Patrick L.} and Decheng Yang",
year = "2006",
month = "12",
day = "1",
doi = "10.1128/JVI.00900-06",
language = "English (US)",
volume = "80",
pages = "11510--11519",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "23",

}

TY - JOUR

T1 - Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site

AU - Yuan, Ji

AU - Stein, David A.

AU - Lim, Travis

AU - Qiu, Dexin

AU - Coughlin, Shaun

AU - Liu, Zhen

AU - Wang, Yinjing

AU - Blouch, Robert

AU - Moulton, Hong M.

AU - Iversen, Patrick L.

AU - Yang, Decheng

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Coxsackievirus B3 (CVB3) is a primary cause of viral myocarditis, yet no effective therapeutic against CVB3 is available. Nucleic acid-based interventional strategies against various viruses, including CVB3, have shown promise experimentally, but limited stability and inefficient delivery in vivo remain as obstacles to their potential as therapeutics. We employed phosphorodiamidate morpholino oligomers (PMO) conjugated to a cell-penetrating arginine-rich peptide, P007 (to form PPMO), to address these issues. Eight CVB3-specifflc PPMO were evaluated with HeLa cells and HL-1 cardiomyocytes in culture and in a murine infection model. One of the PPMO (PPMO-6), designed to target a sequence in the 3′ portion of the CVB3 internal ribosomal entry site, was found to be especially potent against CVB3. Treatment of cells with PPMO-6 prior to CVB3 infection produced an approximately 3-log10 decrease in viral titer and largely protected cells from a virus-induced cytopathic effect. A similar antiviral effect was observed when PPMO-6 treatment began shortly after the virus infection period. A/J mice receiving intravenous administration of PPMO-6 once prior to and once after CVB3 infection showed an ∼2-log10-decreased viral titer in the myocardium at 7 days postinfection and a significantly decreased level of cardiac tissue damage, compared to the controls. Thus, PPMO-6 provided potent inhibition of CVB3 amplification both in cell cultures and in vivo and appears worthy of further evaluation as a candidate for clinical development.

AB - Coxsackievirus B3 (CVB3) is a primary cause of viral myocarditis, yet no effective therapeutic against CVB3 is available. Nucleic acid-based interventional strategies against various viruses, including CVB3, have shown promise experimentally, but limited stability and inefficient delivery in vivo remain as obstacles to their potential as therapeutics. We employed phosphorodiamidate morpholino oligomers (PMO) conjugated to a cell-penetrating arginine-rich peptide, P007 (to form PPMO), to address these issues. Eight CVB3-specifflc PPMO were evaluated with HeLa cells and HL-1 cardiomyocytes in culture and in a murine infection model. One of the PPMO (PPMO-6), designed to target a sequence in the 3′ portion of the CVB3 internal ribosomal entry site, was found to be especially potent against CVB3. Treatment of cells with PPMO-6 prior to CVB3 infection produced an approximately 3-log10 decrease in viral titer and largely protected cells from a virus-induced cytopathic effect. A similar antiviral effect was observed when PPMO-6 treatment began shortly after the virus infection period. A/J mice receiving intravenous administration of PPMO-6 once prior to and once after CVB3 infection showed an ∼2-log10-decreased viral titer in the myocardium at 7 days postinfection and a significantly decreased level of cardiac tissue damage, compared to the controls. Thus, PPMO-6 provided potent inhibition of CVB3 amplification both in cell cultures and in vivo and appears worthy of further evaluation as a candidate for clinical development.

UR - http://www.scopus.com/inward/record.url?scp=33751211238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751211238&partnerID=8YFLogxK

U2 - 10.1128/JVI.00900-06

DO - 10.1128/JVI.00900-06

M3 - Article

C2 - 16987987

AN - SCOPUS:33751211238

VL - 80

SP - 11510

EP - 11519

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 23

ER -